<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03774238</url>
  </required_header>
  <id_info>
    <org_study_id>UF7699</org_study_id>
    <nct_id>NCT03774238</nct_id>
  </id_info>
  <brief_title>Determinants of the Vascular Response to Training in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <acronym>cDysEndoBPCO</acronym>
  <official_title>Biological and Functional Determinants of the Endothelial and Vascular Response to Exercise Training in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular comorbidities constitute a major burden in COPD patients. The atherosclerosis
      process is preceded by the onset of an endothelial dysfunction (assessed by the flow-mediated
      dilatation (FMD)), which is a risk factor for later ischemic vascular complications and
      death. In COPD, this endothelial dysfunction could be explained by intrinsic endothelial cell
      properties, or the effect of a pathogenic endothelial cell microenvironment (inflammation
      and/or oxidative stress). While exercise training is an efficient intervention in COPD
      patients, its vascular effect appear blunted. The endothelial function response to training
      has appeared heterogeneous in COPD patients, and possibly linked to the endothelial cel
      lesion. Thus, endothelial function (assessed by the FMD) response to exercise training would
      be lower in COPD patients with a baseline impairment of the their FMD. In addition, of
      biological and functional factors could explained the magnitude of the FMD response in COPD
      patients.The aim of the study is thus :

      To compare the FMD change in COPD patients with FMD above and under the median FMD after 4
      weeks of exercise training in the whole study population.

      To test the association between the magnitude of the FMD changes after training and
      biological, functional and clinical factors (inflammation oxidative stress markers,
      endothelial biomarkers, pulmonary impairment and phenotype, cardiovascular risks factors,
      vascular function, metabolic markers, physical activity level, …)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of Flow-Mediated Dilatation (FMD)</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Measure of FMD by EndoPAT2000©</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of biological vascular markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>E-selectin soluble (sE-sel, ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of biological vascular markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Angiopoietin 1 (Ang-1, ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of biological vascular markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Angiopoietin 2 (Ang-2, ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of biological vascular markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>von Willebrand factor (vWF, IU/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of biological vascular markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Endothelin1 (ET1, pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of biological vascular markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>vascular endothelial growth factor A (VEGF-A, pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of biological vascular markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Fms-like tyrosine kinase receptor 1 soluble (sFlt-1, pg/mL])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function vascular markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Intima-media thickness (in mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function vascular markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Pulse-wave velocity (in ms−1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function vascular markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Systolic pressure index (in AU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of systemic inflammatory markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>high-sensitivity C-reactive protein (hs-CRP) (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of systemic inflammatory markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Tumor Necrosis Factor (TNF-a) (µg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of systemic inflammatory markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Interleukin-1 (IL-1) (in pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of systemic inflammatory markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Interleukin-6 (IL-6) (in pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of oxidative stress markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Lipid peroxidation (μmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of oxidative stress markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Plasma-free and esterified isoprostanes (pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of oxidative stress markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Glutathione (GSH)/glutathione disulfide (GSSG) ratio (in AU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of oxidative stress markers</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Antioxidant enzymatic (catalase, glutathione peroxidase, in International Unit (UI/gHb))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function assessment</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Maximum isometric voluntary contraction (knee-flexion: 90°, in N.m)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function assessment</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Endurance time (load : 30% of the maximum strength, in sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity parameters</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Six minute walking distance (in meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity parameters</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Exercise and rest blood pressure (in mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity parameters</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Maximal oxygen uptake (VO2max, in mL/kg/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of fasting metabolic parameters</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Glycemia (in mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of fasting metabolic parameters</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Insulinemia (in pmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of fasting metabolic parameters</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Triglycerides (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of fasting metabolic parameters</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>Cholesterol (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of fasting metabolic parameters</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>HDL cholesterol (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of fasting metabolic parameters</measure>
    <time_frame>4 +/- 2 weeks</time_frame>
    <description>LDL cholesterol (mmol/L)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>COPD Patients</condition>
  <arm_group>
    <arm_group_label>COPD patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FMD analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FMD analysis</intervention_name>
    <description>Blood sample and vascular exploration.</description>
    <arm_group_label>COPD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 35 and 85 years old

          -  COPD patients with a spirometry confirmed diseased

          -  COPD patients with an indication for a pulmonary rehabilitation program

          -  written and informed consent for this study signed by the patient

        Exclusion Criteria:

          -  Unstabilized comorbidity

          -  Subject in a period of exclusion relative to another protocol

          -  Major protected by law

          -  Subject participating in another research protocol

          -  Subject not affiliated to a social security scheme

          -  Pregnant or lactating woman

          -  Patient deprived of freedom by court or administrative order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fares Gouzi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fares Gouzi, MD, PhD</last_name>
    <phone>+33467335908</phone>
    <email>f-gouzi@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montpellier and Nimes University Hospitals</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fares Gouzi, MD, phD</last_name>
      <phone>+33 4 67 33 59 08</phone>
      <email>f-gouzi@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flow-mediated dilatation</keyword>
  <keyword>COPD</keyword>
  <keyword>Pulmonary Rehabilitation</keyword>
  <keyword>Comorbidities</keyword>
  <keyword>endothelial cell</keyword>
  <keyword>oxidative stress</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

